Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
Divij Mathew(Parker Institute for Cancer Immunotherapy), Andy J. Minn(Memorial Sloan Kettering Cancer Center), Wei‐Ting Hwang(California University of Pennsylvania), Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), Reem Ghinnagow(Cancer Research Institute), Nancy R. Zhang(University of the Arts), Melina E. Marmarelis(University of Pennsylvania), Erica L. Carpenter(University of Pennsylvania), Christiana Davis(University of Pennsylvania), Soyeong Jun(Stanford University), Caitlin Foley(Cancer Research Institute), Shin Foong Ngiow(Parker Institute for Cancer Immunotherapy), E. John Wherry(Parker Institute for Cancer Immunotherapy), Joshua Bauml(University of Pennsylvania), Josephine R. Giles(Parker Institute for Cancer Immunotherapy), Alexander C. Huang(University of Pennsylvania), Max Klapholz(Parker Institute for Cancer Immunotherapy), Corey J. Langer(University of Pennsylvania), Zhaojun Zhang(University of Pennsylvania), Darwin Ye(Cancer Research Institute), Maximillian Diehn(Stanford University), Robert Zorc(Translational Therapeutics (United States))
Cited by 205
Related Papers
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
|Science|2020|1.7k
Acquired Resistance to Immune Checkpoint Inhibitors
|Cancer Cell|2020|927
T cell responses in patients with COVID-19
|Nature reviews. Immunology|2020|873
Comprehensive mapping of immune perturbations associated with severe COVID-19
|Science Immunology|2020|801